Quantichrom creatinine kit

Serum levels and urinary excretion of ETP (S-ETP and U-ETP) were measured using a competitive ELISA, PRO-C6, according to manufacturer's instructions (Nordic Bioscience, Herlev, Denmark) [24 (link), 32 (link)]. DKK-3 was measured in serum (S-DKK-3) and urine (U-DKK-3) with a Human DKK-3 ELISA Kit (Sigma Aldrich, St Louis, MO, USA) in the laboratories of the General University Hospital. Urine Cr levels were measured with the QuantiChrom™ Creatinine kit (BioAssay Systems) and U-ETP as well as U-DKK-3 levels were normalized for urine Cr (U-ETP/Cr and U-DKK-3/Cr). Serum and urine samples for ETP and DKK-3 measurements were not available for all 49 IgAN (S-ETP n = 49, U-ETP n = 47, S-DKK-3, n = 47; U-DKK-3, n = 39) and 47 AAV patients (S-ETP n = 47, U-ETP, n = 44; S-DKK-3, n = 45; U-DKK-3, n = 37), or for the 85 IgAN patients included in the validation cohort (S-ETP, n = 85; U-ETP, n = 61).

Bood samples were taken from the retro-ocular venous plexus at 6 hours or 24 hours after reperfusion. Renal function was then assessed by determining the creatinine concentration in plasma using a QuantiChrom Creatinine kit (BioAssay Systems, Hayward, CA, USA) [14 (link)15 (link)16 (link)18 (link)19 (link)].

Blood samples were taken from the retro-ocular vein plexus at 1, 2, or 3 days after cisplatin injection. Renal function was then assessed by determining the concentration of plasma creatinine using a QuantiChrom Creatinine kit (Bio-Assay Systems, Hayward, CA, USA) [22 (link), 23 (link)].